Anna Hansson - SenzaGen Chief Commercial Officer
| SENZA Stock | SEK 4.98 0.02 0.40% |
Executive
Ms. Anna Cherouvrier Hansson was Chief Commercial Officer at SenzaGen AB since 2017. Anna Cherouvrier Hansson holds a European Masters degree in Business Administration from Lund University and a Bachelors degree in Business Administration from the European Partnership of Business Schools, Groupe ESC Reims, France and Fachhochschule Reutlingen, Germany. Anna Cherouvrier Hansson has extensive experience in the pharmaceutical industry and has previously worked with commercialization and business development at a number of companies including Camurus AB and Invest in Skane AB. In addition, Anna Cherouvrier Hansson was one of four partners at Zitha Consulting AB, working on behalf of pharmaceutical companies and their commercialization strategies. She has international employment experience and has previously worked in Denmark, Luxembourg and Germany. since 2017.
| Age | 50 |
| Tenure | 8 years |
| Phone | 46 4 62 75 60 00 |
| Web | https://senzagen.com |
SenzaGen Management Efficiency
The company has return on total asset (ROA) of (0.1691) % which means that it has lost $0.1691 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3224) %, meaning that it generated substantial loss on money invested by shareholders. SenzaGen's management efficiency ratios could be used to measure how well SenzaGen manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | EXECUTIVE Age | ||
| Pia Renaudin | Senzime AB | 56 | |
| Rianne Waninge | Senzime AB | N/A | |
| Anders Jacobson | Senzime AB | 56 | |
Management Performance
| Return On Equity | -0.32 | |||
| Return On Asset | -0.17 |
SenzaGen AB Leadership Team
Elected by the shareholders, the SenzaGen's board of directors comprises two types of representatives: SenzaGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SenzaGen. The board's role is to monitor SenzaGen's management team and ensure that shareholders' interests are well served. SenzaGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SenzaGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marisa Meloni, Founder Srl | ||
| Tina Lawesson, IR and Communications Director | ||
| Anna Hansson, Chief Commercial Officer | ||
| Helen Olsson, VP HR | ||
| Asa Nyhlen, VP Operations | ||
| Henrik Johansson, Chief Scientist | ||
| Marianne Olsson, Chief Financial Officer | ||
| Peter Nahlstedt, Director |
SenzaGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SenzaGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | |||
| Return On Asset | -0.17 | |||
| Profit Margin | (1.02) % | |||
| Operating Margin | (0.95) % | |||
| Current Valuation | 255.67 M | |||
| Shares Outstanding | 24.19 M | |||
| Shares Owned By Insiders | 37.29 % | |||
| Shares Owned By Institutions | 8.24 % | |||
| Price To Book | 3.31 X | |||
| Price To Sales | 10.69 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for SenzaGen Stock Analysis
When running SenzaGen's price analysis, check to measure SenzaGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SenzaGen is operating at the current time. Most of SenzaGen's value examination focuses on studying past and present price action to predict the probability of SenzaGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SenzaGen's price. Additionally, you may evaluate how the addition of SenzaGen to your portfolios can decrease your overall portfolio volatility.